Cancer Research Cancer Epigenetics Genetics and Biology of Brain Cancer
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Cancer Research Clinical Cancer Research
Cancer Epidemiology Biomarkers & Prevention Molecular Cancer Therapeutics
Molecular Cancer Research Cancer Prevention Research
Cancer Prevention Journals Portal Cancer Reviews Online
Annual Meeting Education Book Meeting Abstracts Online
This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Molina, M. A.
Right arrow Articles by Baselga, J.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Molina, M. A.
Right arrow Articles by Baselga, J.
[Cancer Research 61, 4744-4749, June 15, 2001]
© 2001 American Association for Cancer Research

Experimental Therapeutics

Trastuzumab (Herceptin), a Humanized Anti-HER2 Receptor Monoclonal Antibody, Inhibits Basal and Activated HER2 Ectodomain Cleavage in Breast Cancer Cells1

Miguel A. Molina, Jordi Codony-Servat, Joan Albanell, Federico Rojo, Joaquín Arribas and Jose Baselga2

Laboratory of Oncology Research, Medical Oncology Service [M. A. M., J. C-S., J. A., F. R., J. A., J. B.], and Universitat Autonoma de Barcelona [J. B.], Vall d’Hebron University Hospital, 08035 Barcelona, Spain

HER2 is a ligand-less tyrosine kinase receptor of the ErbB family that is frequently overexpressed in breast cancer. It undergoes proteolytic cleavage that results in the release of the extracellular domain and the production of a truncated membrane-bound fragment, p95. We show that HER2 shedding is activated by 4-aminophenylmercuric acetate (APMA), a well-known matrix metalloprotease activator, in HER2-overexpressing breast cancer cells. The HER2 p95 fragment, which appears after APMA-induced cleavage, is phosphorylated. We analyzed 24 human breast cancer specimens, and a phosphorylated Mr 95,000 HER2 band could be detected in some of them, which indicated that the truncated receptor is also present in vivo. The activation of HER2 shedding by APMA in cells was blocked with batimastat, a broad-spectrum metalloprotease inhibitor. Trastuzumab (Herceptin; Genentech, San Francisco, CA), a humanized monoclonal antibody directed at the HER2 ectodomain, which has been shown to be active in patients with HER2-overexpressing breast cancer, inhibited basal and induced HER2 cleavage and, as a consequence, the generation of phosphorylated p95. This inhibitory effect of trastuzumab was not shared by 2C4, an antibody against a different epitope of the HER2 ectodomain. The inhibition of basal and APMA-induced cleavage of HER2 by trastuzumab preceded antibody-induced receptor down-modulation, which indicated that the effect of trastuzumab on cleavage was not attributable to a decrease in cell-surface HER2 induced by trastuzumab. We propose that the inhibition of HER2 cleavage and prevention of the production of an active truncated HER2 fragment represent a novel mechanism of action of trastuzumab.




This article has been cited by other articles:


Home page
 JCOHome page
N. L. Spector and K. L. Blackwell
Understanding the Mechanisms Behind Trastuzumab Therapy for Human Epidermal Growth Factor Receptor 2-Positive Breast Cancer
J. Clin. Oncol., December 1, 2009; 27(34): 5838 - 5847.
[Abstract] [Full Text] [PDF]

Home page
 JCOHome page
R. S. Finn, R. Gagnon, A. Di Leo, M. F. Press, M. Arbushites, and M. Koehler
Prognostic and Predictive Value of HER2 Extracellular Domain in Metastatic Breast Cancer Treated With Lapatinib and Paclitaxel in a Randomized Phase III Study
J. Clin. Oncol., November 20, 2009; 27(33): 5552 - 5558.
[Abstract] [Full Text] [PDF]

Home page
 Mol. Cell. Biol.Home page
K. Pedersen, P.-D. Angelini, S. Laos, A. Bach-Faig, M. P. Cunningham, C. Ferrer-Ramon, A. Luque-Garcia, J. Garcia-Castillo, J. L. Parra-Palau, M. Scaltriti, et al.
A Naturally Occurring HER2 Carboxy-Terminal Fragment Promotes Mammary Tumor Growth and Metastasis
Mol. Cell. Biol., June 15, 2009; 29(12): 3319 - 3331.
[Abstract] [Full Text] [PDF]

Home page
 Clin. Cancer Res.Home page
L. C. Benavides, J. D. Gates, M. G. Carmichael, R. Patel, J. P. Holmes, M. T. Hueman, E. A. Mittendorf, D. Craig, A. Stojadinovic, S. Ponniah, et al.
The Impact of HER2/neu Expression Level on Response to the E75 Vaccine: From U.S. Military Cancer Institute Clinical Trials Group Study I-01 and I-02
Clin. Cancer Res., April 15, 2009; 15(8): 2895 - 2904.
[Abstract] [Full Text] [PDF]

Home page
 JCOHome page
S. Lennon, C. Barton, L. Banken, L. Gianni, M. Marty, J. Baselga, and B. Leyland-Jones
Utility of Serum HER2 Extracellular Domain Assessment in Clinical Decision Making: Pooled Analysis of Four Trials of Trastuzumab in Metastatic Breast Cancer
J. Clin. Oncol., April 1, 2009; 27(10): 1685 - 1693.
[Abstract] [Full Text] [PDF]

Home page
 JCOHome page
A. F. Leary, W. M. Hanna, M. J. van de Vijver, F. Penault-Llorca, J. Ruschoff, R. Y. Osamura, M. Bilous, and M. Dowsett
Value and Limitations of Measuring HER-2 Extracellular Domain in the Serum of Breast Cancer Patients
J. Clin. Oncol., April 1, 2009; 27(10): 1694 - 1705.
[Abstract] [Full Text] [PDF]

Home page
 Endocr Relat CancerHome page
C. F Singer, G. Hudelist, E.-M. Fuchs, W. Kostler, A. Fink-Retter, D. Gschwantler-Kaulich, M. Gnant, W. Lamm, M. Rudas, K. Czerwenka, et al.
Incomplete surgical resection of ductal carcinomas in situ results in activation of ERBB2 in residual breast cancer cells
Endocr. Relat. Cancer, March 1, 2009; 16(1): 73 - 83.
[Abstract] [Full Text] [PDF]

Home page
 Clin. Cancer Res.Home page
F. L. Chen, W. Xia, and N. L. Spector
Acquired Resistance to Small Molecule ErbB2 Tyrosine Kinase Inhibitors
Clin. Cancer Res., November 1, 2008; 14(21): 6730 - 6734.
[Abstract] [Full Text] [PDF]

Home page
 Ann OncolHome page
V. Ludovini, S. Gori, M. Colozza, L. Pistola, E. Rulli, I. Floriani, E. Pacifico, F. R. Tofanetti, A. Sidoni, C. Basurto, et al.
Evaluation of serum HER2 extracellular domain in early breast cancer patients: correlation with clinicopathological parameters and survival
Ann. Onc., May 1, 2008; 19(5): 883 - 890.
[Abstract] [Full Text] [PDF]

Home page
 aacredbookHome page
N. E Hynes
ErbB Receptors in Cancer: HER2/ErbB2 as a Therapeutic Target
Am. Assoc. Cancer Res. Educ. Book, April 12, 2008; 2008(1): 123 - 130.
[Abstract] [Full Text] [PDF]

Home page
 Clin. Cancer Res.Home page
A. Ocana and A. Pandiella
Identifying Breast Cancer Druggable Oncogenic Alterations: Lessons Learned and Future Targeted Options
Clin. Cancer Res., February 15, 2008; 14(4): 961 - 970.
[Abstract] [Full Text] [PDF]

Home page
 J. Am. Soc. Nephrol.Home page
Z. Zhang, B. D. Humphreys, and J. V. Bonventre
Shedding of the Urinary Biomarker Kidney Injury Molecule-1 (KIM-1) Is Regulated by MAP Kinases and Juxtamembrane Region
J. Am. Soc. Nephrol., October 1, 2007; 18(10): 2704 - 2714.
[Abstract] [Full Text] [PDF]

Home page
 Clin. Cancer Res.Home page
C. A. Ritter, M. Perez-Torres, C. Rinehart, M. Guix, T. Dugger, J. A. Engelman, and C. L. Arteaga
Human Breast Cancer Cells Selected for Resistance to Trastuzumab In vivo Overexpress Epidermal Growth Factor Receptor and ErbB Ligands and Remain Dependent on the ErbB Receptor Network
Clin. Cancer Res., August 15, 2007; 13(16): 4909 - 4919.
[Abstract] [Full Text] [PDF]

Home page
 NEJMHome page
C. A. Hudis
Trastuzumab -- Mechanism of Action and Use in Clinical Practice
N. Engl. J. Med., July 5, 2007; 357(1): 39 - 51.
[Full Text] [PDF]

Home page
 JCOHome page
B. P. Coudert, R. Largillier, L. Arnould, P. Chollet, M. Campone, D. Coeffic, F. Priou, J. Gligorov, X. Martin, V. Trillet-Lenoir, et al.
Multicenter Phase II Trial of Neoadjuvant Therapy With Trastuzumab, Docetaxel, and Carboplatin for Human Epidermal Growth Factor Receptor-2 Overexpressing Stage II or III Breast Cancer: Results of the GETN(A)-1 Trial
J. Clin. Oncol., July 1, 2007; 25(19): 2678 - 2684.
[Abstract] [Full Text] [PDF]

Home page
 Ann OncolHome page
G Valabrega, F Montemurro, and M Aglietta
Trastuzumab: mechanism of action, resistance and future perspectives in HER2-overexpressing breast cancer
Ann. Onc., June 1, 2007; 18(6): 977 - 984.
[Abstract] [Full Text] [PDF]

Home page
 JNCI J Natl Cancer InstHome page
M. Scaltriti, F. Rojo, A. Ocana, J. Anido, M. Guzman, J. Cortes, S. Di Cosimo, X. Matias-Guiu, S. Ramon y Cajal, J. Arribas, et al.
Expression of p95HER2, a Truncated Form of the HER2 Receptor, and Response to Anti-HER2 Therapies in Breast Cancer
J Natl Cancer Inst, April 18, 2007; 99(8): 628 - 638.
[Abstract] [Full Text] [PDF]

Home page
 Clin. Cancer Res.Home page
E. Suzuki, R. Niwa, S. Saji, M. Muta, M. Hirose, S. Iida, Y. Shiotsu, M. Satoh, K. Shitara, M. Kondo, et al.
A Nonfucosylated Anti-HER2 Antibody Augments Antibody-Dependent Cellular Cytotoxicity in Breast Cancer Patients
Clin. Cancer Res., March 15, 2007; 13(6): 1875 - 1882.
[Abstract] [Full Text] [PDF]

Home page
 J. Immunol.Home page
K. Furuuchi, A. Berezov, T. Kumagai, and M. I. Greene
Targeted Antireceptor Therapy with Monoclonal Antibodies Leads to the Formation of Inactivated Tetrameric Forms of ErbB Receptors
J. Immunol., January 15, 2007; 178(2): 1021 - 1029.
[Abstract] [Full Text] [PDF]

Home page
 J. Biol. Chem.Home page
C. Zahnd, F. Pecorari, N. Straumann, E. Wyler, and A. Pluckthun
Selection and Characterization of Her2 Binding-designed Ankyrin Repeat Proteins
J. Biol. Chem., November 17, 2006; 281(46): 35167 - 35175.
[Abstract] [Full Text] [PDF]

Home page
 Clin. Cancer Res.Home page
C. Swanton, A. Futreal, and T. Eisen
Her2-targeted therapies in non-small cell lung cancer.
Clin. Cancer Res., July 15, 2006; 12(14): 4377s - 4383s.
[Abstract] [Full Text] [PDF]

Home page
 Ann OncolHome page
G. Gasparini, R. Sarmiento, S. Amici, R. Longo, D. Gattuso, M. Zancan, and M. Gion
Gefitinib (ZD1839) combined with weekly epirubicin in patients with metastatic breast cancer: a phase I study with biological correlate
Ann. Onc., December 1, 2005; 16(12): 1867 - 1873.
[Abstract] [Full Text] [PDF]

Home page
 Ann OncolHome page
J. P. Delord, C. Allal, M. Canal, E. Mery, P. Rochaix, I. Hennebelle, A. Pradines, E. Chatelut, R. Bugat, S. Guichard, et al.
Selective inhibition of HER2 inhibits AKT signal transduction and prolongs disease-free survival in a micrometastasis model of ovarian carcinoma
Ann. Onc., December 1, 2005; 16(12): 1889 - 1897.
[Abstract] [Full Text] [PDF]

Home page
 JCOHome page
D. B. Agus, M. S. Gordon, C. Taylor, R. B. Natale, B. Karlan, D. S. Mendelson, M. F. Press, D. E. Allison, M. X. Sliwkowski, G. Lieberman, et al.
Phase I Clinical Study of Pertuzumab, a Novel HER Dimerization Inhibitor, in Patients With Advanced Cancer
J. Clin. Oncol., April 10, 2005; 23(11): 2534 - 2543.
[Abstract] [Full Text] [PDF]

Home page
 aacredbookHome page
M. D. Pegram
Molecular Determinants of Trastuzumab Response/Resistance
Am. Assoc. Cancer Res. Educ. Book, April 1, 2005; 2005(1): 155 - 159.
[Full Text] [PDF]

Home page
 Cancer Res.Home page
P. Nagy, E. Friedlander, M. Tanner, A. I. Kapanen, K. L. Carraway, J. Isola, and T. M. Jovin
Decreased Accessibility and Lack of Activation of ErbB2 in JIMT-1, a Herceptin-Resistant, MUC4-Expressing Breast Cancer Cell Line
Cancer Res., January 15, 2005; 65(2): 473 - 482.
[Abstract] [Full Text] [PDF]

Home page
 Mol. Biol. CellHome page
C. D. Austin, A. M. De Maziere, P. I. Pisacane, S. M. van Dijk, C. Eigenbrot, M. X. Sliwkowski, J. Klumperman, and R. H. Scheller
Endocytosis and Sorting of ErbB2 and the Site of Action of Cancer Therapeutics Trastuzumab and Geldanamycin
Mol. Biol. Cell, December 1, 2004; 15(12): 5268 - 5282.
[Abstract] [Full Text] [PDF]

Home page
 Protein Eng Des SelHome page
T. Olafsen, G. J. Tan, C.-w. Cheung, P. J. Yazaki, J. M. Park, J. E. Shively, L. E. Williams, A. A. Raubitschek, M. F. Press, and A. M. Wu
Characterization of engineered anti-p185HER-2 (scFv-CH3)2 antibody fragments (minibodies) for tumor targeting
Protein Eng. Des. Sel., April 1, 2004; 17(4): 315 - 323.
[Abstract] [Full Text] [PDF]

Home page
 Mol. Biol. CellHome page
A. M. Hommelgaard, M. Lerdrup, and B. van Deurs
Association with Membrane Protrusions Makes ErbB2 an Internalization-resistant Receptor
Mol. Biol. Cell, April 1, 2004; 15(4): 1557 - 1567.
[Abstract] [Full Text] [PDF]

Home page
 Clin. Cancer Res.Home page
W. J. Kostler, B. Schwab, C. F. Singer, R. Neumann, E. Rucklinger, T. Brodowicz, S. Tomek, M. Niedermayr, M. Hejna, G. G. Steger, et al.
Monitoring of Serum Her-2/neu Predicts Response and Progression-Free Survival to Trastuzumab-Based Treatment in Patients with Metastatic Breast Cancer
Clin. Cancer Res., March 1, 2004; 10(5): 1618 - 1624.
[Abstract] [Full Text] [PDF]

Home page
 Clin. Cancer Res.Home page
R. Nahta and F. J. Esteva
HER-2-Targeted Therapy: Lessons Learned and Future Directions
Clin. Cancer Res., November 1, 2003; 9(14): 5078 - 5084.
[Abstract] [Full Text] [PDF]

Home page
 Clin. Chem.Home page
W. P. Carney, R. Neumann, A. Lipton, K. Leitzel, S. Ali, and C. P. Price
Potential Clinical Utility of Serum HER-2/neu Oncoprotein Concentrations in Patients with Breast Cancer
Clin. Chem., October 1, 2003; 49(10): 1579 - 1598.
[Abstract] [Full Text] [PDF]

Home page
 Clin. Cancer Res.Home page
A. M. Bajo, A. V. Schally, G. Halmos, and A. Nagy
Targeted Doxorubicin-containing Luteinizing Hormone-releasing Hormone Analogue AN-152 Inhibits the Growth of Doxorubicin-resistant MX-1 Human Breast Cancers
Clin. Cancer Res., September 1, 2003; 9(10): 3742 - 3748.
[Abstract] [Full Text] [PDF]

Home page
 J. Biol. Chem.Home page
V. Bailly, Z. Zhang, W. Meier, R. Cate, M. Sanicola, and J. V. Bonventre
Shedding of Kidney Injury Molecule-1, a Putative Adhesion Protein Involved in Renal Regeneration
J. Biol. Chem., October 11, 2002; 277(42): 39739 - 39748.
[Abstract] [Full Text] [PDF]

Home page
 Clin. Chem.Home page
S. M. Ali, K. Leitzel, V. M. Chinchilli, L. Engle, L. Demers, H. A. Harvey, W. Carney, J. W. Allard, and A. Lipton
Relationship of Serum HER-2/neu and Serum CA 15-3 in Patients with Metastatic Breast Cancer
Clin. Chem., August 1, 2002; 48(8): 1314 - 1320.
[Abstract] [Full Text] [PDF]

Home page
 Clin. Cancer Res.Home page
A. E. Frankel
New HER2-directed Therapies for Breast Cancer.: Commentary re: C. I. Spiridon et al., Targeting Multiple Her-2 Epitopes with Monoclonal Antibodies Results in Improved Antigrowth Activity. Clin. Cancer Res., 8: 1720-1730, 2002.
Clin. Cancer Res., June 1, 2002; 8(6): 1699 - 1701.
[Full Text] [PDF]

Home page
 Clin. Cancer Res.Home page
C. I. Spiridon, M.-A. Ghetie, J. Uhr, R. Marches, J.-L. Li, G.-L. Shen, and E. S. Vitetta
Targeting Multiple Her-2 Epitopes with Monoclonal Antibodies Results in Improved Antigrowth Activity of a Human Breast Cancer Cell Line in Vitro and in Vivo
Clin. Cancer Res., June 1, 2002; 8(6): 1720 - 1730.
[Abstract] [Full Text] [PDF]

Home page
 Proc. Natl. Acad. Sci. USAHome page
A. M. Bajo, A. V. Schally, M. Krupa, F. Hebert, K. Groot, and K. Szepeshazi
Bombesin antagonists inhibit growth of MDA-MB-435 estrogen-independent breast cancers and decrease the expression of the ErbB-2/HER-2 oncoprotein and c-jun and c-fos oncogenes
PNAS, March 19, 2002; 99(6): 3836 - 3841.
[Abstract] [Full Text] [PDF]

Home page
 JNCI J Natl Cancer InstHome page
J. Albanell and J. Baselga
Unraveling Resistance to Trastuzumab (Herceptin): Insulin-Like Growth Factor-I Receptor, a New Suspect
J Natl Cancer Inst, December 19, 2001; 93(24): 1830 - 1832.
[Full Text] [PDF]

Home page
 Clin. Cancer Res.Home page
J. Baselga
Is Circulating HER-2 More Than Just a Tumor Marker?
Clin. Cancer Res., September 1, 2001; 7(9): 2605 - 2607.
[Full Text] [PDF]


HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Cancer Research Clinical Cancer Research
Cancer Epidemiology Biomarkers & Prevention Molecular Cancer Therapeutics
Molecular Cancer Research Cancer Prevention Research
Cancer Prevention Journals Portal Cancer Reviews Online
Annual Meeting Education Book Meeting Abstracts Online
Copyright © 2001 by the American Association for Cancer Research.